onc Videos

Videos

Peter O'Donnell, MD, University of Chicago

Videos

Efficacy and Safety of Pembrolizumab for Metastatic Urothelial Carcinoma

01/17/2023

Peter O’Donnell, MD, discusses an analysis from from the KEYNOTE-045 and KEYNOTE-052 trials, showing continued efficacy and safety of pembrolizumab for patients with metastatic urothelial carcinoma after 5 years of follow-up.

Peter O’Donnell, MD, discusses...

01/17/2023

Oncology

Videos

Ibrutinib Plus Venetoclax Induces High Rates of MRD Negativity in IGHV-Unmutated CLL

01/16/2023

Talha Munir, MD, discusses findings from an updated interim analysis of the FLAIR study at the 2022 ASH Annual Meeting & Exposition in New Orleans, LA.

Talha Munir, MD, discusses...

01/16/2023

Oncology

Videos

Polatuzumab Vedotin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

01/16/2023

Christopher R. Flowers, MD, MD Anderson Cancer Center, Houston, TX discusses the results of the GO29365 study on polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma.

Christopher R. Flowers, MD, MD...

01/16/2023

Oncology

Rachel Jimenez, MD, Massachusetts General Hospital

Videos

Advances in Radiotherapy for Patients With Breast Cancer

01/10/2023

At the 2022 San Antonio Breast Cancer Symposium, Rachel Jimenez, MD, reviews updates and advancements in radiotherapy technology for patients with breast cancer.

At the 2022 San Antonio Breast...

01/10/2023

Oncology

Per Karlsson, MD, PhD, Sahlgrenska Comprehensive Cancer Center

Videos

Prognostic Value of the POLAR Scores for Radiotherapy Benefit Among Patients with HR-Positive, HER2-Negative Breast Cancer

01/10/2023

At the 2022 San Antonio Breast Cancer Symposium, Per Karlsson, MD, PhD presents results from the meta-analysis investigating the prognostic value of POLAR scores in predicting the benefit of radiotherapy for patients with breast cancer.

At the 2022 San Antonio Breast...

01/10/2023

Oncology

Aditya Bardia, MD, Mass General Cancer Center

Conference Coverage

Identifying Endocrine-Sensitive Disease in HR-Positive Metastatic Breast Cancer

01/10/2023

At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of elacestrant vs standard of care endocrine therapy for patients with ER-positive, HER2-negative, metastatic breast cancer by duration of prior...

At the 2022 San Antonio Breast...

01/10/2023

Oncology

Videos

Proton Therapy as a Radiation Option to Reduce Cardiac Toxicity in Breast Cancer

01/06/2023

Rachel Jimenez, MD, discusses an upcoming clinical trial examining the efficacy of advanced radiation technology in reducing radiation-related toxicity for patients with breast cancer.

Rachel Jimenez, MD, discusses an...

01/06/2023

Oncology

Lyudmila Bazhenova, MD, University of California San Diego

Videos

The Importance of Biomarker Testing for Patients With NSCLC

01/05/2023

Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss their approaches to biomarker testing for patients newly diagnosed with NSCLC, the role of tissue vs liquid biopsy, and how these biomarkers are used to inform treatment decisions.

Edward Garon, MD, and Lyudmila...

01/05/2023

Oncology

Edward Garon, MD, University of California Los Angeles

Videos

Frontline Management of NSCLC After Approval of Durvalumab Plus Tremelimumab and Chemotherapy

12/22/2022

Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss options for frontline management of NSCLC after the most recent approval of durvalumab plus tremelimumab and chemotherapy based on results from the POSEIDON trial.

Edward Garon, MD, and Lyudmila...

12/22/2022

Oncology

Sara Hurvitz, MD, David Geffen School of Medicine

Videos

Trastuzumab Deruxtecan for HR-Positive, HER2-Low, Early-Stage Breast Cancer

12/22/2022

At the 2022 San Antonio Breast Cancer Symposium, Sara Hurvitz, MD, presents preliminary results from the TRIO-US B-12 TALENT trial, investigating trastuzumab deruxtecan for patients with HR-positive, HER2-low, early-stage breast cancer.

At the 2022 San Antonio Breast...

12/22/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology